Bavarian Nordic A/S (OTCMKTS:BVNRY) Short Interest Down 11.3% in August

Bavarian Nordic A/S (OTCMKTS:BVNRYGet Rating) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 21,100 shares, a decrease of 11.3% from the August 15th total of 23,800 shares. Based on an average trading volume of 503,900 shares, the short-interest ratio is presently 0.0 days.

Analysts Set New Price Targets

Separately, Cowen upgraded shares of Bavarian Nordic A/S from a “market perform” rating to an “outperform” rating in a report on Wednesday, July 20th.

Bavarian Nordic A/S Stock Performance

Shares of BVNRY stock opened at $9.95 on Monday. Bavarian Nordic A/S has a 52-week low of $5.85 and a 52-week high of $19.31. The company has a 50-day simple moving average of $14.04 and a two-hundred day simple moving average of $10.66. The company has a market capitalization of $2.10 billion, a price-to-earnings ratio of -20.73 and a beta of 1.49.

About Bavarian Nordic A/S

(Get Rating)

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.

Recommended Stories

Receive News & Ratings for Bavarian Nordic A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic A/S and related companies with MarketBeat.com's FREE daily email newsletter.